SCYNEXIS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ, 07302-6548
Mailing Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ, 07302-6548
Phone
201-884-5485
Fiscal Year End
1231
EIN
562181648
Financial Overview
FY2025
$35.57M
Total Liabilities
$72.96M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 8, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 7, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 4, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 2, 2026 | View on SEC |
Annual Reports
10-K
March 4, 2026
- Positive Phase 3 results and sNDA submission for Brexafemme's expanded indication, targeting broader market access.
- Significant revenue growth in 2025, reaching $15.5 million, driven by Brexafemme sales and partnership milestones.
Insider Trading
NEUTRAL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.